SG11202109734SA - N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use - Google Patents
N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic useInfo
- Publication number
- SG11202109734SA SG11202109734SA SG11202109734SA SG11202109734SA SG 11202109734S A SG11202109734S A SG 11202109734SA SG 11202109734S A SG11202109734S A SG 11202109734SA SG 11202109734S A SG11202109734S A SG 11202109734SA
- Authority
- SG
- Singapore
- Prior art keywords
- sulfonylmethyl
- piperidine
- acyl
- aryl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905520.1A GB201905520D0 (en) | 2019-04-18 | 2019-04-18 | Compounds and their therapeutic use |
| PCT/EP2020/060879 WO2020212581A1 (en) | 2019-04-18 | 2020-04-17 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109734SA true SG11202109734SA (en) | 2021-10-28 |
Family
ID=66810170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109734S SG11202109734SA (en) | 2019-04-18 | 2020-04-17 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230022917A1 (ja) |
| EP (1) | EP3956030A1 (ja) |
| JP (1) | JP2022528799A (ja) |
| KR (1) | KR20220002871A (ja) |
| CN (1) | CN113766953A (ja) |
| AU (1) | AU2020257561A1 (ja) |
| BR (1) | BR112021016672A2 (ja) |
| CA (1) | CA3132265C (ja) |
| EA (1) | EA202192032A1 (ja) |
| GB (1) | GB201905520D0 (ja) |
| IL (1) | IL287279A (ja) |
| MA (1) | MA55713A (ja) |
| MX (1) | MX2021012743A (ja) |
| SG (1) | SG11202109734SA (ja) |
| WO (1) | WO2020212581A1 (ja) |
| ZA (1) | ZA202106236B (ja) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753679A (en) | 1995-05-10 | 1998-05-19 | Hoffmann-La Roche Inc. | Benzyl-piperidine derivatives |
| IL151124A0 (en) * | 2000-03-21 | 2003-04-10 | Procter & Gamble | Heterocyclic side chain containing metalloprotease inhibitors |
| WO2003053941A2 (en) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| JPWO2007102392A1 (ja) | 2006-03-03 | 2009-07-23 | 塩野義製薬株式会社 | Ｍｍｐ−１３選択的阻害剤 |
| PE20080932A1 (es) * | 2006-11-10 | 2008-07-13 | Wyeth Corp | Piperidinil 4-arilsulfonamidas n-sustituidas como moduladores de la proteina 1 secretada relacionada con frizzled (sfrp-1) |
| JP5330260B2 (ja) | 2006-12-06 | 2013-10-30 | スミスクライン ビーチャム コーポレーション | 二環式化合物ならびに抗糖尿病薬としての使用 |
| WO2009020140A1 (ja) | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
| CA2700974A1 (en) | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
| GB0817207D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| PL2858986T3 (pl) | 2012-06-12 | 2020-03-31 | Chong Kun Dang Pharmaceutical Corp. | Pochodne piperydyny jako agoniści GPR119 |
| CA2898107A1 (en) * | 2013-03-06 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| GB201311361D0 (en) * | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| HRP20211877T1 (hr) * | 2014-12-17 | 2022-03-04 | Pimco 2664 Limited | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba |
| PE20171511A1 (es) | 2015-01-22 | 2017-10-20 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) |
-
2019
- 2019-04-18 GB GBGB1905520.1A patent/GB201905520D0/en not_active Ceased
-
2020
- 2020-04-17 JP JP2021560938A patent/JP2022528799A/ja active Pending
- 2020-04-17 AU AU2020257561A patent/AU2020257561A1/en active Pending
- 2020-04-17 KR KR1020217030245A patent/KR20220002871A/ko unknown
- 2020-04-17 CA CA3132265A patent/CA3132265C/en active Active
- 2020-04-17 SG SG11202109734S patent/SG11202109734SA/en unknown
- 2020-04-17 MX MX2021012743A patent/MX2021012743A/es unknown
- 2020-04-17 EA EA202192032A patent/EA202192032A1/ru unknown
- 2020-04-17 MA MA055713A patent/MA55713A/fr unknown
- 2020-04-17 US US17/602,408 patent/US20230022917A1/en active Pending
- 2020-04-17 CN CN202080029357.6A patent/CN113766953A/zh active Pending
- 2020-04-17 BR BR112021016672-6A patent/BR112021016672A2/pt unknown
- 2020-04-17 EP EP20720038.7A patent/EP3956030A1/en active Pending
- 2020-04-17 WO PCT/EP2020/060879 patent/WO2020212581A1/en active Application Filing
-
2021
- 2021-08-27 ZA ZA2021/06236A patent/ZA202106236B/en unknown
- 2021-10-14 IL IL287279A patent/IL287279A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201905520D0 (en) | 2019-06-05 |
| CA3132265A1 (en) | 2020-10-22 |
| ZA202106236B (en) | 2023-05-31 |
| JP2022528799A (ja) | 2022-06-15 |
| BR112021016672A2 (pt) | 2021-10-13 |
| WO2020212581A1 (en) | 2020-10-22 |
| MA55713A (fr) | 2022-02-23 |
| IL287279A (en) | 2021-12-01 |
| US20230022917A1 (en) | 2023-01-26 |
| CN113766953A (zh) | 2021-12-07 |
| EA202192032A1 (ru) | 2022-03-10 |
| CA3132265C (en) | 2023-12-19 |
| EP3956030A1 (en) | 2022-02-23 |
| AU2020257561A1 (en) | 2021-10-28 |
| KR20220002871A (ko) | 2022-01-07 |
| MX2021012743A (es) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2586940B (en) | Therapeutic compositions | |
| IL286079A (en) | History of imidazolonylquiniline and their medical uses | |
| EP3917910A4 (en) | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | |
| GB202001980D0 (en) | Therapeutic mentods | |
| EP3873444A4 (en) | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | |
| EP3866786A4 (en) | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATMENT OF METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | |
| EP3796928A4 (en) | TREATMENT OF GAUCHER DISEASE | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| EP4055014A4 (en) | PYRROLIDINE AND PIPERIDINE COMPOUNDS | |
| EP3919472A4 (en) | DEZOCINE DERIVATIVE AND ITS MEDICAL USE | |
| GB202006960D0 (en) | Therapeutic | |
| EP3927328A4 (en) | INHALED THERAPEUTIC | |
| EP3908275A4 (en) | RAPIDLY DISCOUNTING ORAL TABLET | |
| IL287279A (en) | n-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their medical use | |
| EP3873446A4 (en) | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | |
| GB201918541D0 (en) | Therapeutic compounds and their use | |
| EP3749662A4 (en) | COMPOUNDS AND THERAPEUTIC COMPOSITIONS | |
| EP3958833A4 (en) | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | |
| EP4027988A4 (en) | OPIOID-INDEPENDENT SURGICAL ANESTHESIC | |
| EP3938053A4 (en) | EPITOPE-BASED APPROACH TO ALLERGY TREATMENTS AND CROHN'S DISEASE INHIBITORS | |
| ZA202101490B (en) | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use | |
| GB202314048D0 (en) | New pharmaceutical use | |
| GB202213577D0 (en) | New pharmaceutical use | |
| EP3886848A4 (en) | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | |
| GB202113078D0 (en) | New pharmaceutical use |